Therefore, the discovery of an inhibitor of LIX1L, such as shRNA, homeodomain peptides and inhibitors of specific ROS1 kinases would be useful to identify potential tumor-specific drugs for LIX1L-expressing cancer cells. This evidence concerns the gene LIX1L and neoplasm.